NCT03641755 2026-02-23
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT00590187 2024-06-04
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Cyclacel Pharmaceuticals, Inc.
Phase 2 Completed
NCT01303796 2022-06-22
SEAMLESS
Cyclacel Pharmaceuticals, Inc.
Phase 3 Completed
NCT00476554 2021-12-22
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00885963 2021-12-22
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Cyclacel Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00999401 2021-12-22
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT00380653 2021-12-13
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT01253460 2019-09-06
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01211457 2019-07-16
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown